Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat.
Publication
, Journal Article
Armstrong, PW; Ezekowitz, JA
Published in: JACC Heart Fail
May 2021
Duke Scholars
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
May 2021
Volume
9
Issue
5
Start / End Page
403
Location
United States
Related Subject Headings
- Pyrimidines
- Humans
- Heterocyclic Compounds, 2-Ring
- Heart Failure
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, P. W., & Ezekowitz, J. A. (2021). Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat. JACC Heart Fail, 9(5), 403. https://doi.org/10.1016/j.jchf.2021.03.001
Armstrong, Paul W., and Justin A. Ezekowitz. “Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat.” JACC Heart Fail 9, no. 5 (May 2021): 403. https://doi.org/10.1016/j.jchf.2021.03.001.
Armstrong PW, Ezekowitz JA. Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat. JACC Heart Fail. 2021 May;9(5):403.
Armstrong, Paul W., and Justin A. Ezekowitz. “Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat.” JACC Heart Fail, vol. 9, no. 5, May 2021, p. 403. Pubmed, doi:10.1016/j.jchf.2021.03.001.
Armstrong PW, Ezekowitz JA. Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat. JACC Heart Fail. 2021 May;9(5):403.
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
May 2021
Volume
9
Issue
5
Start / End Page
403
Location
United States
Related Subject Headings
- Pyrimidines
- Humans
- Heterocyclic Compounds, 2-Ring
- Heart Failure
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology